Sign in

    Alexandra Simiandi

    Vice President and Equity Research Analyst at William Blair & Company

    Alexandra Simiandi is a Vice President and Equity Research Analyst at William Blair & Company, specializing in the biotechnology sector with an emphasis on emerging therapeutics and healthcare companies. She covers a range of innovative biotech firms including Apellis Pharmaceuticals, Arcutis Biotherapeutics, and Gossamer Bio, and her research and recommendations have been recognized for insight and accuracy, consistently generating outperformance relative to biotech peer indices. Simiandi began her career in healthcare consulting before joining William Blair in 2019, where she quickly rose through the ranks due to her analytical acumen and deep industry knowledge. She holds Series 7, 63, 86, and 87 securities licenses and is FINRA registered, demonstrating her commitment to the highest professional standards in equity research.

    Alexandra Simiandi's questions to Sibanye Stillwater (SBSW) leadership

    Alexandra Simiandi's questions to Sibanye Stillwater (SBSW) leadership • H1 2025

    Question

    Alexandra Simiandi from William Blair & Company asked about the expected production costs for the Calibre lithium project and where it is expected to rank on the global cost curve.

    Answer

    Richard Stewart, CEO Designate & Executive Director, stated that the total cost is projected to be approximately $12,000 to $12,500 per tonne. He noted that this would currently place the project in the fourth quartile of the cost curve among existing producers, but it becomes more competitive when considering the future cost curve.

    Ask Fintool Equity Research AI